BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 9565447)

  • 1. Hepatorenal syndrome.
    Bataller R; Arroyo V; Ginès P; Sort P
    Forum (Genova); 1998; 8(1):62-81. PubMed ID: 9565447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatorenal syndrome.
    Bataller R; Ginès P; Guevara M; Arroyo V
    Semin Liver Dis; 1997; 17(3):233-47. PubMed ID: 9308128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatorenal syndrome.
    Biswas KD; Jain AK
    Trop Gastroenterol; 2002; 23(3):113-6. PubMed ID: 12693150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and treatment of hepatorenal syndrome.
    Ginès P
    Baillieres Best Pract Res Clin Gastroenterol; 2000 Dec; 14(6):945-57. PubMed ID: 11139348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatorenal syndrome: a dreaded complication of end-stage liver disease.
    Cárdenas A
    Am J Gastroenterol; 2005 Feb; 100(2):460-7. PubMed ID: 15667508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatorenal syndrome.
    Bataller R; Ginès P; Arroyo V; Rodés J
    Clin Liver Dis; 2000 May; 4(2):487-507. PubMed ID: 11232202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatorenal syndrome.
    Kramer L; Hörl WH
    Semin Nephrol; 2002 Jul; 22(4):290-301. PubMed ID: 12118394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatorenal syndrome.
    Cárdenas A; Arroyo V
    Ann Hepatol; 2003; 2(1):23-9. PubMed ID: 15094702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathophysiology and treatment of hepatorenal syndrome.
    Wong F; Blendis L
    Gastroenterologist; 1998 Jun; 6(2):122-35. PubMed ID: 9660529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatorenal syndrome.
    Guevara M; Rodés J
    Int J Biochem Cell Biol; 2005 Jan; 37(1):22-6. PubMed ID: 15381144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: pharmacological treatment of hepatorenal syndrome.
    Ginès P; Torre A; Terra C; Guevara M
    Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():57-62; discussion 63-4. PubMed ID: 15335404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome.
    Arroyo V; Terra C; Ginès P
    J Hepatol; 2007 May; 46(5):935-46. PubMed ID: 17391801
    [No Abstract]   [Full Text] [Related]  

  • 14. The management of hepatorenal syndrome.
    Carl DE; Sanyal A
    Minerva Gastroenterol Dietol; 2009 Jun; 55(2):207-26. PubMed ID: 19305378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatments of hepatorenal syndrome.
    Arroyo V; Terra C; Ginès P
    Semin Liver Dis; 2006 Aug; 26(3):254-64. PubMed ID: 16850375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy insight: Management of hepatorenal syndrome.
    Cárdenas A; Ginès P
    Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):338-48. PubMed ID: 16741553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in hepatorenal syndrome.
    Arroyo V; Torre A; Guevara M
    Trop Gastroenterol; 2005; 26(1):13-20. PubMed ID: 15974232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatorenal syndrome].
    Mijac D; Kezić A; Stojimirović B
    Srp Arh Celok Lek; 2007; 135(1-2):98-104. PubMed ID: 17503577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis.
    Salerno F; Guevara M; Bernardi M; Moreau R; Wong F; Angeli P; Garcia-Tsao G; Lee SS
    Liver Int; 2010 Aug; 30(7):937-47. PubMed ID: 20492521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
    Wong F; Raina N; Richardson R
    Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.